In conclusion, our study showed that mitochondrial GNMT expression plays an important role in the pathogenesis of NAFLD, and combination of an inducer of GNMT and metformin can be an effective regimen to treat NAFLD. The gene discussed is GNMT; the disease is metabolic dysfunction-associated steatotic liver disease.